myirislogo
05 September, 2015 13:12 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 225.05 3.25
Icici Bank 257.85 3.37
Tata Stl 218.95 4.66
Hindalco In 73.85 4.34
Axis Bank 468.85 3.61
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Ajanta Pharma Limited
Ajanta Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532331NSE:AJANTPHARMBloomberg:AJP@INReuters:AJPH.BO
Market Lot: 1Face Value: 2ISIN Demat: INE031B01049
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
04-AUG-15 Ajanta Pharma, a company engaged in manufacturing & marketing of pharmaceutical products, announced that it has received final approval for its 3 ANDAs (Abbreviated New Drug Application) by US FDA (US Food & Drug Administration). 08-MAY-15 Ajanta Pharma, a company engaged in manufacturing & marketing of pharmaceutical products, reported a gain of 20.29% in net profit for the quarter ended Mar. 31, 2015. 28-JAN-15 During the quarter...   More..
Business Profile Future Plans
CEO Talk
Ajanta Pharma is a typical niche player. The company?s managing director Purushottam Agrawal is confident of Ajanta Pharma logging in a growth of at least 15 per cent in its topline and much higher than that in its bottomline.   Purushottam Agrawal
One To One
Recent news
Latest News
Ajanta Pharma surges 5% after receiving USFDA approval  -IRIS 04-Aug-15
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2015(3)31-Mar-2015 (12)31-Mar-2014 (12)
Net sales 3348.8013286.2010798.70
Other Income135.30337.00177.20
Total Income3484.1013623.2010975.90
Cost of goods sold2307.708836.407643.90
OPBDIT1176.404786.803332.00
PAT810.603063.702208.60
Gross Block---
Equity capital176.90176.80176.70
EPS (Rs.)-34.8462.83
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-27.64 - 99.029.95 - 18.73
Debt / Equity (x)---
Operating margin (% of OI)33.835.130.4
Net margin (% of OI)23.322.520.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Ajanta House
Charkop
Kandivli (West)
Mumbai
Maharashtra-400 067
PHONE
(022) 6606 1000/ 1204/ 1203
FAX
(022) 6606 1200/ 1300
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer